No photo of Christopher McCann
  • Room 03.013 - CCRCB

    United Kingdom

20182019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Christopher McCann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Caspase 8 Medicine & Life Sciences
CASP8 and FADD-Like Apoptosis Regulating Protein Medicine & Life Sciences
Inhibitor of Apoptosis Proteins Medicine & Life Sciences
caspase-8 Agriculture & Biology
Death Domain Receptors Medicine & Life Sciences
Death Domain Receptor Signaling Adaptor Proteins Medicine & Life Sciences
Adjuvant Chemotherapy Medicine & Life Sciences
Receptor Mathematics

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2018 2019

41 Downloads (Pure)

Heterogeneous responses to low level death receptor activation are explained by random molecular assembly of the Caspase-8 activation platform

Matveeva, A., Fichtner, M., McAllister, K., McCann, C., Sturrock, M., Longley, D. B. & Prehn, J. H. M., 25 Sep 2019, In : PLoS Computational Biology. 15, 9, 22 p., e1007374.

Research output: Contribution to journalArticle

Open Access
File
caspase-8
Death Domain Receptors
Death Domain Receptor Signaling Adaptor Proteins
Caspase 8
Receptor
3 Citations (Scopus)
157 Downloads (Pure)

Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists

McCann, C., Crawford, N., Majkut, J., Holohan, C., Armstrong, C., Maxwell, P., Ong, C. W., LaBonte Wilson, M., McDade, S., Waugh, D. & Longley, D., 22 Oct 2018, In : Cell, Death & Disease. 9, 1081, 13 p., 1081.

Research output: Contribution to journalArticle

Open Access
File
CASP8 and FADD-Like Apoptosis Regulating Protein
Inhibitor of Apoptosis Proteins
Prostatic Neoplasms
Apoptosis
Caspase 8
239 Downloads (Pure)

Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy

Allen, W., Dunne, P., McDade, S., Scanlon, E., Loughrey, M., Coleman, H., McCann, C., McLaughlin, K., Nemeth, Z., Syed, N. A., Jithesh, P. V., Arthur, K., Wilson, R., Coyle, V., McArt, D., Johnston, P., Murray, G. I., Samuel, L. M., Nuciforo, P., Jimenez, J. & 12 others, Argiles, G., Dienstmann, R., Picariello, L., Nobili, S., Mini, E., Sheahan, K., Ryan, E., Tabernero, J., Messerini, L., Van Schaeybroeck, S., Lawler, M. & Longley, D., 13 Jun 2018, In : JCO Precision Oncology. 2018, p. 1-15

Research output: Contribution to journalArticle

Open Access
File
Adjuvant Chemotherapy
Colorectal Neoplasms
Immunohistochemistry
Standard of Care
Neoplasms